EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis

Stephen A Harrison, Vlad Ratziu iD, Quentin M Anstee iD, Mazen Noureddin, Arun J Sanyal iD, Jörn M Schattenberg iD, Pierre Bedossa, Mustafa R Bashir, David Schneider, Rebecca Taub, Meena Bansal, Kris V Kowdley and 2 more

Alimentary Pharmacology & Therapeutics · 2024-01 · 59 (1) · 51-63

DOI: 10.1111/apt.17734 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, published online on 2023-10-02. Written by Stephen A Harrison and 13 co-authors. Institution: Pinnacle Clinical Research Center, San Antonio, Texas, USA. Major MEDLINE topics: Non-alcoholic Fatty Liver Disease. Cited 96 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Madrigal Pharmaceuticals.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Non‐alcoholic steatohepatitis (NASH) is a progressive form of non‐alcoholic fatty liver disease (NAFLD) associated with steatosis, hepatocellular injury, inflammation and fibrosis. In a Phase 2 trial in adults with NASH (NCT02912260), resmetirom, an orally administered, liver‐targeted thyroid hormone receptor‐β selective agonist, significantly reduced hepatic fat (via imaging) and resolved NASH without worsening fibrosis (via liver biopsy) in a significant number of patients compared with placebo.

Aims

To present the design of the Phase 3 MAESTRO clinical programme evaluating resmetirom for treatment of NASH (MAESTRO‐NAFLD‐1 [NCT04197479], MAESTRO‐NAFLD‐OLE [NCT04951219], MAESTRO‐NASH [NCT03900429], MAESTRO‐NASH‐OUTCOMES [NCT05500222]).

Methods

MAESTRO‐NASH is a pivotal serial biopsy trial in up to 2000 adults with biopsy‐confirmed at‐risk NASH. Patients are randomised to a once‐daily oral placebo, 80 mg resmetirom, or 100 mg resmetirom. Liver biopsies are conducted at screening, week 52 and month 54. MAESTRO‐NAFLD‐1 is a 52‐week safety trial in ~1400 adults with NAFLD/presumed NASH (based on non‐invasive testing); ~700 patients from MAESTRO‐NAFLD‐1 are enrolled in MAESTRO‐NAFLD‐OLE, a 52‐week active treatment extension to further evaluate safety. MAESTRO‐NASH‐OUTCOMES is enrolling 700 adults with well‐compensated NASH cirrhosis to evaluate the potential for resmetirom to slow progression to hepatic decompensation events. Non‐invasive tests (biomarkers, imaging) are assessed longitudinally throughout, in addition to validated patient‐reported outcomes.

Conclusion

The MAESTRO clinical programme was designed in conjunction with regulatory authorities to support approval of resmetirom for treatment of NASH. The surrogate endpoints, based on week 52 liver biopsy, serum biomarkers and imaging, are confirmed by long‐term clinical liver‐related outcomes in MAESTRO‐NASH (month 54) and MAESTRO‐NASH‐OUTCOMES (time to event).

Subjects

MeSH terms (MEDLINE)

Non-alcoholic Fatty Liver DiseaseAdultHumansLiverLiver CirrhosisBiomarkersRandomized Controlled Trials as TopicPyridazinesUracil

Substances

BiomarkersresmetiromPyridazinesUracil

Authors and institutions

  • Pinnacle Clinical Research Center, San Antonio, Texas, USA.
  • Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Sorbonne University, Paris, France.
  • Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle-Upon-Tyne, UK.
  • Houston Research Institute, Houston Methodist Hospital, Houston, Texas, USA.
  • Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.

ORCID profiles: Vlad Ratziu, Quentin M Anstee, Arun J Sanyal, Jörn M Schattenberg, Zobair M Younossi

Funding

  • Madrigal Pharmaceuticals

Cite

APA

Harrison, S. A., Ratziu, V., Anstee, Q. M., Noureddin, M., Sanyal, A. J., Schattenberg, J. M., Bedossa, P., Bashir, M. R., Schneider, D., Taub, R., Bansal, M., Kowdley, K. V., Younossi, Z. M., & Loomba, R. (2024). Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics, 59(1), 51-63. https://doi.org/10.1111/apt.17734

Vancouver

Harrison SA, Ratziu V, Anstee QM, Noureddin M, Sanyal AJ, Schattenberg JM, et al. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics. 2024;59(1):51-63. doi:10.1111/apt.17734

BibTeX
@article{Harrison2024,
  author = {Harrison, Stephen A and Ratziu, Vlad and Anstee, Quentin M and Noureddin, Mazen and Sanyal, Arun J and Schattenberg, Jörn M and Bedossa, Pierre and Bashir, Mustafa R and Schneider, David and Taub, Rebecca and Bansal, Meena and Kowdley, Kris V and Younossi, Zobair M and Loomba, Rohit},
  title = {Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {59},
  number = {1},
  pages = {51--63},
  doi = {10.1111/apt.17734}
}
Start for free →